Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Declaring your medication is a helpful first step
In its third-quarter results update this week, Novo Nordisk also revealed it has now filed for approval of oral semaglutide in the EU for launch in "selected markets," and sees the drug as "a big step forward in terms of expanding the market and for those individuals that align better with taking a pill for their obesity." Both companies have been investing heavily in direct-to-consumer (DTC) sales channels for cash purchasing of their current injectable products, and Novo Nordisk said on the call it will make oral semaglutide available across all its sales channels if approved.
For nutritional use only
Dihexa crosses the blood-brain barrier and activates the hepatocyte growth factor (HGF) / c-Met receptor pathway, which governs neuron survival and synapse formation
Mark Fendrick, who directs the Center for Value-Based Insurance Design at the University of Michigan and has written extensively about GLP-1s, describes the drugs as "remarkable
